Oxford Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Oxford Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Sell	5,478 -9,299	-63%	-$509K	0.15%	196
2026 Q1	$835K	Buy	+14,777	New	+$862K	0.34%	69
2025 Q4	–	Sell	-10,426	Closed	-$565K	–	528
2025 Q3	$565K	Sell	10,426 -14,310	-58%	-$818K	0.19%	170
2025 Q2	$1.36M	Buy	+24,736	New	+$1.46M	0.45%	38
2019 Q3	–	Sell	-61,908	Closed	-$5.3M	–	1717
2019 Q2	$5.3M	Buy	+61,908	New	+$5.3M	0.11%	215
2018 Q4	–	Sell	-11,492	Closed	-$1.12M	–	1789
2018 Q3	$1.12M	Buy	11,492 +188	+2%	+$18.8K	0.02%	953
2018 Q2	$1.06M	Buy	+11,304	New	+$990K	0.02%	1011
2018 Q1	–	Sell	-9,629	Closed	-$859K	–	1620
2017 Q4	$859K	Buy	9,629 +4,780	+99%	+$416K	0.02%	996
2017 Q3	$452K	Buy	+4,849	New	+$428K	0.01%	1230
2015 Q2	–	Sell	-10,672	Closed	-$1.33M	–	668
2015 Q1	$1.33M	Sell	10,672 -23,282	-69%	-$2.47M	0.03%	418
2014 Q4	$3.13M	Buy	+33,954	New	+$2.82M	0.07%	279

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Oxford Asset Management's BMRN Position: Q2 2026 in Review

Oxford Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 63% in Q2 2026, selling an estimated $509K and leaving 5,478 shares worth $313K. The position accounts for 0.15% of the portfolio, ranked #196.

Oxford Asset Management first reported a position in BMRN in Q4 2014 and has held it in 11 quarters since. The position peaked at $5.3M in Q2 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Oxford Asset Management held 5,478 shares of BioMarin Pharmaceuticals worth $313K as of Q2 2026.
Oxford Asset Management sold 9,299 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $509K.
BioMarin Pharmaceuticals made up 0.15% of Oxford Asset Management's portfolio in Q2 2026, its #196 holding.
Oxford Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
Oxford Asset Management's BioMarin Pharmaceuticals position peaked at $5.3M in Q2 2019.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.